Ozempic, Wegovy, Mounjaro — and what naturopathic medicine can actually do instead.

A clinical naturopath’s evidence-based guide to natural GLP-1 support, insulin sensitivity and metabolic health

By Cassandra Hilton — Clinical Naturopath, Canberra

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and liraglutide — have dominated health conversations for the past three years. They are genuinely effective medications for type 2 diabetes and obesity, with a growing evidence base that extends to cardiovascular and kidney disease. They are also expensive, frequently supply-constrained, associated with significant gastrointestinal side effects, and require indefinite use to maintain results — with weight typically returning within twelve months of stopping.

The question I’m asked frequently in my Canberra naturopathic practice is this: “is there a natural alternative?” The honest answer is nuanced. There is no natural compound that replicates the pharmacological potency of semaglutide. But there are evidence-based nutritional and herbal medicine strategies that support GLP-1 physiology naturally, improve insulin sensitivity, reduce appetite signalling and support sustainable metabolic health — and for people who are not candidates for GLP-1 medications, or who want to support their results, or who simply want to address the underlying metabolic drivers, these strategies are clinically meaningful.

This article explains how GLP-1 works, what the research actually shows for natural approaches, and how I apply this in clinical practice.

What GLP-1 is and why it matters

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by enteroendocrine L-cells in the distal small intestine and colon in response to food intake. It has three primary actions: stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, and slowing gastric emptying — which together reduce post-meal blood glucose spikes. At the central nervous system level, GLP-1 acts on hypothalamic receptors to reduce appetite and promote satiety.

A 2025 comprehensive review published in Pharmaceutics (Patel & Niazi) confirmed that GLP-1 receptor agonists have evolved from glucose-lowering agents to transformative therapies across multiple organ systems, including cardiovascular, hepatic and renal protection. The pharmacological versions of GLP-1 — semaglutide, tirzepatide and others — achieve their effects by binding to the same GLP-1 receptor but at concentrations far exceeding what the body produces naturally, and with much longer half-lives than endogenous GLP-1 (which degrades within minutes).

This is the key distinction: natural approaches cannot replicate the sustained, supraphysiological receptor activation that pharmaceutical GLP-1 agonists achieve. What they can do is support the body’s own GLP-1 production and improve the downstream metabolic mechanisms that GLP-1 influences.

The gut microbiome — where natural GLP-1 support begins

GLP-1 is produced by L-cells, and L-cell activity is profoundly influenced by the gut microbiome. A 2026 review in the British Journal of Clinical Pharmacology (Kamath et al.) confirmed that short-chain fatty acids (SCFAs) — particularly butyrate and propionate — produced by gut bacteria through the fermentation of dietary fibre, stimulate GLP-1 secretion by binding to free fatty acid receptors FFAR2 (GPR43) and FFAR3 (GPR41) on L-cell surfaces. The microbial taxa most important for this process include Faecalibacterium prausnitzii, Roseburia inulinivorans and Bacteroides species.

A 2024 review in mBio (Zeng et al.) confirmed that changes in gut microbiota composition and function are consistently observed in both obesity and type 2 diabetes — and that restoring microbial diversity and SCFA-producing capacity is a legitimate pathway to improving endogenous GLP-1 secretion.

What this means practically: the foundation of natural GLP-1 support is a high-fibre, plant-diverse diet that feeds the SCFA-producing bacteria responsible for stimulating L-cell GLP-1 release. This is not a supplement strategy — it is a dietary and microbiome strategy.

Akkermansia muciniphila — the emerging keystone strain

Akkermansia muciniphila is a mucin-degrading gut bacterium that has emerged as one of the most clinically significant strains in metabolic health research. Human studies have shown that even pasteurised, non-viable forms of Akkermansia improve insulin sensitivity and support gut barrier integrity, with research demonstrating a 28.6% improvement in insulin sensitivity in overweight individuals with insulin resistance. Akkermansia abundance is reduced in obesity, type 2 diabetes and metabolic syndrome, and is increased by dietary fibre, polyphenols and intermittent fasting. Supplementation with pasteurised Akkermansia is now available in practitioner-grade formulations.

Berberine — the most evidence-supported natural metabolic compound

Berberine is a plant alkaloid found in Berberis vulgaris (barberry), Berberis aristata (Indian barberry) and Coptis chinensis (goldenseal). It has been used in Chinese and Ayurvedic medicine for centuries and has accumulated one of the strongest evidence bases of any natural compound in metabolic medicine. It is frequently described as “nature’s Ozempic” — a label that is partially justified by the evidence and partially overstated.

What the research shows

A 2024 systematic review and meta-analysis of 50 randomised controlled trials involving 4,150 participants, published in Phytomedicine, found that berberine alone significantly reduced fasting plasma glucose (MD −0.59 mmol/L), 2-hour post-prandial blood glucose (MD −1.57 mmol/L), LDL cholesterol (MD −0.30 mmol/L), total cholesterol (MD −0.30 mmol/L) and triglycerides (MD −0.35 mmol/L).

A 2024 umbrella meta-analysis in Clinical Therapeutics (Nazari et al.) confirmed that berberine supplementation significantly reduced fasting blood glucose, HbA1c, HOMA-IR (insulin resistance index), insulin, IL-6, TNF-α and CRP — addressing both glycaemic control and the inflammatory burden that drives metabolic disease.

The mechanisms are well-characterised. Berberine activates AMP-activated protein kinase (AMPK) — the same energy-sensing enzyme activated by exercise and caloric restriction — enhancing glucose uptake in peripheral tissues. It also increases intestinal L-cell GLP-1 production, as confirmed by research showing berberine stimulates the β-catenin/TCF4 signalling pathway in intestinal L-cells. A 2025 systematic review in Frontiers in Pharmacology confirmed berberine’s effects across multiple components of metabolic syndrome, including waist circumference, blood pressure, fasting glucose and lipids.

How berberine differs from pharmaceutical GLP-1 agonists

Berberine’s weight loss effects are modest compared to semaglutide. A meta-analysis of 12 RCTs found berberine associated with approximately 2kg of weight loss and 1cm reduction in waist circumference. Semaglutide at therapeutic doses produces 10–15% body weight reduction in clinical trials. These are not equivalent interventions.

What berberine does offer that pharmaceutical GLP-1 agonists do not: direct lipid-lowering effects independent of weight loss, anti-inflammatory activity, gut microbiome support, hepatoprotective effects in non-alcoholic fatty liver disease, and a significantly lower cost and side effect profile. It is best understood as a metabolic medicine in its own right — not as a substitute for semaglutide, but as a clinically meaningful intervention for insulin resistance, dyslipidaemia and metabolic syndrome.

Standard clinical dosing is 500mg two to three times daily with meals. It should not be combined with metformin without medical supervision due to additive glucose-lowering effects, and it requires caution in pregnancy.

Dietary strategies that support GLP-1 naturally

High-protein meals and GLP-1 secretion

Protein is one of the strongest dietary stimulants of GLP-1 secretion. A protein-rich breakfast — 30g or more — significantly improves post-meal satiety and blunts the glycaemic response to subsequent meals across the day. Whey protein in particular has been shown to stimulate GLP-1 and GIP secretion acutely. Eating protein first within a meal (before carbohydrates) reduces post-meal glucose spikes and prolongs satiety signalling.

Dietary fibre — the most important single dietary change

Research published in Frontiers in Endocrinology (Hunt et al., 2021) confirmed that dietary fibre is essential for maintaining L-cell secretion and intestinal integrity, with fibre-deficient diets producing measurable reductions in GLP-1 production within weeks. The mechanism is SCFA-mediated: gut bacteria ferment soluble fibre into butyrate and propionate, which directly stimulate L-cell GLP-1 release.

Practical targets: 30–35g of dietary fibre per day from diverse sources. Particularly important are resistant starches (cold cooked potatoes, green banana, legumes), psyllium husk, inulin-containing foods (chicory, Jerusalem artichoke, leek, garlic, onion) and beta-glucans (oats, barley). These are selectively fermented by the SCFA-producing bacteria most associated with GLP-1 support.

Vinegar and food sequencing

Apple cider vinegar (1–2 tablespoons in water before a meal) has clinical evidence for reducing post-meal glucose by approximately 20–35% in multiple small trials, through mechanisms including slowing gastric emptying (which reduces the rate of glucose absorption) and improving insulin sensitivity. This is a low-cost, accessible adjunct that complements dietary changes rather than replacing them.

Food sequencing — eating vegetables first, then protein, then carbohydrates — has been shown to reduce post-meal glucose by 28–73% in multiple clinical studies. This is one of the most underused and evidence-supported metabolic interventions available.

Exercise as a GLP-1 and insulin sensitivity strategy

Exercise is one of the most potent natural activators of AMPK — the same pathway berberine activates — and significantly improves insulin sensitivity through mechanisms independent of GLP-1. Resistance training specifically increases GLUT4 transporter expression in muscle tissue, improving glucose uptake without insulin. A 20–30 minute walk after meals reduces post-meal glucose spikes by 20–30% in people with insulin resistance.

The combination of resistance training two to three times per week and post-meal walking is, in metabolic terms, among the most effective interventions available — producing improvements in insulin sensitivity, visceral fat and inflammatory markers that are comparable to low-dose metformin in some trials.

Inositol for insulin resistance and PCOS

Myo-inositol and D-chiro-inositol are insulin sensitisers with a strong evidence base specifically in polycystic ovary syndrome (PCOS), where insulin resistance drives androgen excess and anovulation. A 40:1 ratio of myo-inositol to D-chiro-inositol mirrors the physiological ratio and has been shown in multiple RCTs to improve ovulation rate, reduce androgens, improve metabolic markers and support weight management in PCOS. For women with insulin-resistance-driven metabolic concerns and PCOS, inositol is a first-line naturopathic intervention.

Magnesium — the overlooked metabolic mineral

Magnesium deficiency is present in approximately 50% of people with type 2 diabetes and is consistently associated with insulin resistance. Magnesium is a cofactor in over 300 enzymatic reactions including glucose metabolism and insulin receptor signalling. A systematic review of 18 RCTs found that magnesium supplementation significantly improved fasting glucose and HOMA-IR in people with insulin resistance. The most bioavailable forms are magnesium glycinate and magnesium malate at 300–400mg daily.

Chromium and alpha-lipoic acid

Chromium potentiates insulin action at the receptor level and has been shown in multiple trials to reduce fasting glucose and improve HbA1c in type 2 diabetes. Chromium picolinate at 200–400mcg daily is the most studied form.

Alpha-lipoic acid (ALA) is a mitochondrial antioxidant with insulin-sensitising effects. A 2019 meta-analysis found ALA supplementation at 600–1200mg daily significantly reduced fasting glucose, insulin and HOMA-IR. It is particularly useful in diabetic peripheral neuropathy, where it has the strongest evidence base.

The honest clinical picture

I want to be direct about what natural approaches can and cannot do. For someone with a BMI above 35, established type 2 diabetes and significant cardiovascular risk, pharmaceutical GLP-1 agonists represent a meaningful clinical tool with a risk-benefit profile that often justifies their use. Natural approaches are not an equivalent alternative in this context.

For someone with insulin resistance, pre-diabetes, PCOS-related metabolic concerns, or weight that is driven by chronic inflammation and gut dysbiosis rather than hypothalamic signalling failure — a naturopathic metabolic protocol can produce clinically meaningful and sustainable results, often without the nausea, gastrointestinal disruption and cost of pharmaceutical GLP-1 therapy.

The most important variable is identifying what is actually driving the metabolic concern. Insulin resistance in someone with PCOS and gut dysbiosis responds very differently to treatment than insulin resistance in someone with hypothyroidism and chronic cortisol excess. A thorough metabolic assessment — fasting insulin, HOMA-IR, full lipid panel, thyroid function, inflammatory markers, cortisol rhythm and gut microbiome analysis — determines which interventions are most likely to be effective for a specific individual.

Consulting in Canberra and online across Australia

I offer naturopathic metabolic health consultations in-clinic in Canberra (from October 2026) and via telehealth across Australia and New Zealand. If you’re exploring natural approaches to insulin resistance, metabolic syndrome or weight management, online consultations cover comprehensive metabolic assessment and a targeted protocol. A 15-minute Discovery Call is available to discuss whether this approach is right for your situation.

References

Patel, S., & Niazi, S.K. (2025). Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base. Pharmaceutics, 17(8), 1036. https://doi.org/10.3390/pharmaceutics17081036

Kamath, et al. (2026). GLP-1 agonists and the gut microbiome: a bidirectional relationship. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70487

Zeng, et al. (2024). Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio, 15(1). https://doi.org/10.1128/mbio.02032-23

Li, et al. (2024). Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis of 50 RCTs. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.155825

Nazari, A., et al. (2024). The effect of berberine supplementation on glycemic control and inflammatory biomarkers in metabolic disorders: an umbrella meta-analysis of RCTs. Clinical Therapeutics, 46(2), e64–e72. https://doi.org/10.1016/j.clinthera.2023.10.019

Liu, et al. (2025). Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1572197

Hunt, J.E., et al. (2021). Dietary fiber is essential to maintain intestinal size, L-cell secretion, and intestinal integrity. Frontiers in Endocrinology, 12, 640602. https://doi.org/10.3389/fendo.2021.640602

Wang, et al. (2021). Berberine increases intestinal L-cell GLP-1 production via stimulating the β-catenin/TCF4 signalling pathway. ScienceDirect.

Cassandra Hilton is a clinical naturopath, Western herbalist and nutritional medicine specialist consulting in-clinic in Canberra and via telehealth across Australia and New Zealand. She is the founder of Ocinium cosmeceutical skincare. Bookings at cassandrahilton.com/contact.